This section title reflects a common clinical heading structure but the source article does not report renal endpoints; the preprint focuses on genetic association methods and idiopathic pulmonary fibrosis. The study team did not present data on renal outcomes. The trial metadata and abstract are limited to the development and application of a statistical test for rare-variant association in binary traits and the discovery of a genetic signal for idiopathic pulmonary fibrosis. Data specific to renal measures were not reported in the source document.
Investigators reported a new rare-variant association test called the liability threshold burden test (LTBT). They built LTBT to jointly model the contribution of rare variants and polygenic background using a liability threshold model, rather than treating PRS only as a simple covariate. Simulated datasets were used to evaluate performance. The study team observed that LTBT maintained a well-controlled false positive rate in those simulations. In measures of sensitivity, the simulations indicated that LTBT outperformed existing rare-variant burden tests evaluated by the authors. The authors contrasted LTBT with prior approaches: for binary traits, simply adding a PRS covariate to conventional rare-variant tests had produced limited or no power gain in earlier work, and LTBT was designed to address that gap by explicitly modeling liability.
The source did not provide full technical details of the model implementation, such as exact likelihood formulations, parameter priors, or specific computational workflow steps in the abstract. Likewise, simulation parameter values, sample sizes, and variant inclusion criteria were not reported in the accessible abstract text; those details may appear in the full preprint PDF but were not reproduced in the summary content used here.
The authors applied LTBT to sequencing datasets for idiopathic pulmonary fibrosis (IPF). By accounting for each individual's genetic background with a PRS, they identified a novel association between rare predicted damaging missense variants in HTRA3 (HtrA serine peptidase 3) and IPF. The study team reported that this association was formally replicated in a separate dataset. The preprint frames this finding as gene discovery enabled by a method that better integrates rare-variant signal with polygenic context.
The abstract specifies that the associated variants were rare and predicted to be damaging missense changes; it does not list the exact variants, allele counts, effect sizes, p-values, or the replication cohort characteristics in the summary text. Those analytic and cohort details are not included in the abstract excerpt and therefore cannot be restated here. The study team did note that LTBT showed improved sensitivity in simulations and that this increased detection power coincided with the identification and replication of the HTRA3 signal in IPF sequencing data.
The authors declared that all relevant ethical guidelines were followed, and they reported IRB approval from Mass General Brigham (approval #2016P000837). Consent procedures were confirmed in the author declarations, and the authors reported no competing interests. Funding support included multiple NIH grants listed in the manuscript metadata.
The preprint states that all data produced in the study are available upon reasonable request to the authors. The software developed for LTBT is publicly hosted by the authors at https://github.com/sgchun/ltbt. Those resources are presented as avenues for external groups to inspect, reproduce, or extend the work, subject to any access restrictions the authors may impose.
The manuscript is a medRxiv preprint and has not been certified by peer review; the authors and medRxiv explicitly caution that the findings should not be used to guide clinical practice. The abstract does not provide exhaustive methodological detail in the summary, so external readers will need to consult the full preprint for precise model equations, simulation parameters, and the full sequencing analysis plan. The source did not report certain specifics in the excerpted abstract: exact variant identifiers, effect estimates, p-values, sample sizes for discovery and replication cohorts, or detailed inclusion/exclusion criteria for sequencing datasets.
Questions that remain open and that the source implies require attention include independent validation in additional cohorts beyond the reported replication, transparent reporting of the analytic pipeline and parameters used in LTBT simulations, and further assessment of how LTBT performs across diverse ancestry groups and variant annotation strategies. The authors make software available, which should allow other investigators to reproduce simulations and real-data analyses, but broader community validation and peer review are necessary before translating these findings into clinical genetic testing or risk stratification for idiopathic pulmonary fibrosis.
Ethical oversight, data sharing, and funding are documented in the preprint, and the authors declared no competing interests. The next clear steps implied by the source are public scrutiny through peer review, external replication in additional sequencing cohorts, and detailed methodological review of LTBT's assumptions and performance across scenarios. Until those steps occur, clinicians and researchers should treat the HTRA3–IPF association as a preliminary, albeit replicated within this study, genetic finding described in a preprint.